ATE262898T1 - Formulierung mit gesteuerter wirkstoffabgabe enthaltend bupropion-hci als wirkstoff - Google Patents

Formulierung mit gesteuerter wirkstoffabgabe enthaltend bupropion-hci als wirkstoff

Info

Publication number
ATE262898T1
ATE262898T1 AT02012184T AT02012184T ATE262898T1 AT E262898 T1 ATE262898 T1 AT E262898T1 AT 02012184 T AT02012184 T AT 02012184T AT 02012184 T AT02012184 T AT 02012184T AT E262898 T1 ATE262898 T1 AT E262898T1
Authority
AT
Austria
Prior art keywords
hci
active ingredient
controlled release
release formulation
formulation containing
Prior art date
Application number
AT02012184T
Other languages
English (en)
Inventor
Roberto Valducci
Tiziano Alighieri
Serozh Avanessian
Original Assignee
Valpharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valpharma Sa filed Critical Valpharma Sa
Application granted granted Critical
Publication of ATE262898T1 publication Critical patent/ATE262898T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02012184T 2001-07-09 2002-06-03 Formulierung mit gesteuerter wirkstoffabgabe enthaltend bupropion-hci als wirkstoff ATE262898T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI001457A ITMI20011457A1 (it) 2001-07-09 2001-07-09 Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
CA002391691A CA2391691A1 (en) 2001-07-09 2002-06-26 Modified release pharmaceutical composition containing bupropion hci as active substance

Publications (1)

Publication Number Publication Date
ATE262898T1 true ATE262898T1 (de) 2004-04-15

Family

ID=32991642

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02012184T ATE262898T1 (de) 2001-07-09 2002-06-03 Formulierung mit gesteuerter wirkstoffabgabe enthaltend bupropion-hci als wirkstoff

Country Status (14)

Country Link
US (1) US20030134906A1 (de)
EP (1) EP1275383B1 (de)
JP (1) JP2003048828A (de)
AT (1) ATE262898T1 (de)
AU (1) AU5068202A (de)
BR (1) BR0202759A (de)
CA (1) CA2391691A1 (de)
DE (1) DE60200317T2 (de)
DK (1) DK1275383T3 (de)
ES (1) ES2219602T3 (de)
IL (1) IL149899A0 (de)
IT (1) ITMI20011457A1 (de)
NZ (1) NZ519844A (de)
PT (1) PT1275383E (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN192747B (de) * 2002-04-15 2004-05-15 Ranbaxy Lab Ltd
CN1819821B (zh) * 2003-08-08 2010-10-13 拜奥维尔实验室国际股份有限公司 盐酸安非他酮的改良释放片剂
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393078A (en) * 1982-03-15 1983-07-12 Burroughs Wellcome Co. Bupropion and ethanol
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CA2289190A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
US6635280B2 (en) * 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) * 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
CA2244097A1 (en) * 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation

Also Published As

Publication number Publication date
IL149899A0 (en) 2002-11-10
DE60200317D1 (de) 2004-05-06
ITMI20011457A1 (it) 2003-01-09
DE60200317T2 (de) 2005-02-24
BR0202759A (pt) 2004-05-11
PT1275383E (pt) 2004-06-30
US20030134906A1 (en) 2003-07-17
EP1275383B1 (de) 2004-03-31
NZ519844A (en) 2003-09-26
DK1275383T3 (da) 2004-05-24
AU5068202A (en) 2003-01-16
JP2003048828A (ja) 2003-02-21
CA2391691A1 (en) 2003-12-26
EP1275383A1 (de) 2003-01-15
ITMI20011457A0 (it) 2001-07-09
ES2219602T3 (es) 2004-12-01

Similar Documents

Publication Publication Date Title
NO20054164L (no) Immunoglobulinformulering og fremgangsmåte for fremstilling derav
CY1106943T1 (el) Υποδορια εμφυτευματα τα οποια εμφανιζουν περιορισμενη αρχικη αποδεσμευση του ενεργου συστατικου και ακολουθως γραμμικα μεταβαλλομενη εκτεταμενη αποδεσμευση
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
PT1283700E (pt) Composicoes farmaceuticas de libertacao prolongada destinadas a administracao por via parental de compostos hidrofilos biologicamente activos
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
PL362797A1 (en) Medical aerosol formulations
BRPI0412241A (pt) formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa)
ATE251449T1 (de) Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
ATE334663T1 (de) Arzneimittelzusammensetzung mit verzögerter wirkstoffabgabe
PT1412384E (pt) Formulação estável de glp-1 modificado
MY151121A (en) Hsa-free stabilized interferon liquid formulations
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
ATE361060T1 (de) Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
ATE286736T1 (de) Direktverpressbare matrix zur kontrollierten abgabe von einmaltäglichen dosen von clarithromycin
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
DE60329968D1 (de) Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
EA200901148A1 (ru) Подкожные имплантаты, высвобождающие активные компоненты в течение длительного периода времени
TW200624464A (en) Amphiphilic block copolymer and pharmaceutical formulation comprising the same
DE60200317D1 (de) Formulierung mit gesteuerter Wirkstoffabgabe enthaltend Bupropion-HCI als Wirkstoff
SE0001916D0 (sv) Novel formulation
ATE245974T1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
NZ528544A (en) Formulations comprising entrapped active ingredients and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1275383

Country of ref document: EP

REN Ceased due to non-payment of the annual fee